 Histone Deacetylase Inhibitors
"Histone Deacetylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.
| Descriptor ID |
D056572
|
| MeSH Number(s) |
D27.505.519.389.360
|
| Concept/Terms |
Histone Deacetylase Inhibitors- Histone Deacetylase Inhibitors
- Deacetylase Inhibitors, Histone
- Inhibitors, Histone Deacetylase
- Histone Deacetylase Inhibitor
- Deacetylase Inhibitor, Histone
- Inhibitor, Histone Deacetylase
- HDAC Inhibitors
- Inhibitors, HDAC
|
Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase Inhibitors".
This graph shows the total number of publications written about "Histone Deacetylase Inhibitors" by people in UAMS Profiles by year, and whether "Histone Deacetylase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 | | 2020 | 0 | 2 | 2 | | 2019 | 1 | 2 | 3 | | 2018 | 2 | 1 | 3 | | 2016 | 1 | 1 | 2 | | 2015 | 1 | 1 | 2 | | 2014 | 1 | 2 | 3 | | 2013 | 4 | 3 | 7 | | 2012 | 2 | 1 | 3 | | 2011 | 1 | 3 | 4 | | 2010 | 1 | 1 | 2 | | 2009 | 4 | 2 | 6 | | 2007 | 1 | 2 | 3 | | 2006 | 1 | 1 | 2 | | 2005 | 2 | 0 | 2 | | 2001 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Histone Deacetylase Inhibitors" by people in Profiles over the past ten years.
-
Çakir I, Hadley CK, Pan PL, Bagchi RA, Ghamari-Langroudi M, Porter DT, Wang Q, Litt MJ, Jana S, Hagen S, Lee P, White A, Lin JD, McKinsey TA, Cone RD. Histone deacetylase 6 inhibition restores leptin sensitivity and reduces obesity. Nat Metab. 2022 01; 4(1):44-59.
-
Travers JG, Wennersten SA, Peña B, Bagchi RA, Smith HE, Hirsch RA, Vanderlinden LA, Lin YH, Dobrinskikh E, Demos-Davies KM, Cavasin MA, Mestroni L, Steinkühler C, Lin CY, Houser SR, Woulfe KC, Lam MPY, McKinsey TA. HDAC Inhibition Reverses Preexisting Diastolic Dysfunction and Blocks Covert Extracellular Matrix Remodeling. Circulation. 2021 05 11; 143(19):1874-1890.
-
Brown S, Pawlyn C, Tillotson AL, Sherratt D, Flanagan L, Low E, Morgan GJ, Williams C, Kaiser M, Davies FE, Jenner MW. Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. Clin Lymphoma Myeloma Leuk. 2021 03; 21(3):154-161.e3.
-
Ramos JC, Sparano JA, Chadburn A, Reid EG, Ambinder RF, Siegel ER, Moore PC, Rubinstein PG, Durand CM, Cesarman E, Aboulafia D, Baiocchi R, Ratner L, Kaplan L, Capoferri AA, Lee JY, Mitsuyasu R, Noy A. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood. 2020 09 10; 136(11):1284-1297.
-
Bisagno V, Bernardi MA, Sanz Blasco S, Urbano FJ, Garcia-Rill E. Differential effects of HDAC inhibitors on PPN oscillatory activity in vivo. Neuropharmacology. 2020 03 15; 165:107922.
-
Adams MK, Banks CAS, Miah S, Killer M, Washburn MP. Purification and enzymatic assay of class I histone deacetylase enzymes. Methods Enzymol. 2019; 626:23-40.
-
Bagchi RA, Weeks KL. Histone deacetylases in cardiovascular and metabolic diseases. J Mol Cell Cardiol. 2019 05; 130:151-159.
-
Banks CAS, Miah S, Adams MK, Eubanks CG, Thornton JL, Florens L, Washburn MP. Differential HDAC1/2 network analysis reveals a role for prefoldin/CCT in HDAC1/2 complex assembly. Sci Rep. 2018 09 12; 8(1):13712.
-
Urbano FJ, Bisagno V, Mahaffey S, Lee SH, Garcia-Rill E. Class II histone deacetylases require P/Q-type Ca2+ channels and CaMKII to maintain gamma oscillations in the pedunculopontine nucleus. Sci Rep. 2018 09 03; 8(1):13156.
-
Huang Y, Yang W, Zeng H, Hu C, Zhang Y, Ding N, Fan G, Shao L, Kuang B. Droxinostat sensitizes human colon cancer cells to apoptotic cell death via induction of oxidative stress. Cell Mol Biol Lett. 2018; 23:34.
-
Mishra A, La Perle K, Kwiatkowski S, Sullivan LA, Sams GH, Johns J, Curphey DP, Wen J, McConnell K, Qi J, Wong H, Russo G, Zhang J, Marcucci G, Bradner JE, Porcu P, Caligiuri MA. Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. Cancer Discov. 2016 09; 6(9):986-1005.
-
Debeb BG, Lacerda L, Larson R, Wolfe AR, Krishnamurthy S, Reuben JM, Ueno NT, Gilcrease M, Woodward WA. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget. 2016 May 10; 7(19):28329-39.
-
Khan S, Shukla S, Sinha S, Meeran SM. Epigenetic targets in cancer and aging: dietary and therapeutic interventions. Expert Opin Ther Targets. 2016 Jun; 20(6):689-703.
-
Smith EM, Zhang L, Walker BA, Davenport EL, Aronson LI, Krige D, Hooftman L, Drummond AH, Morgan GJ, Davies FE. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NF?B signalling pathway. Oncotarget. 2015 Jul 10; 6(19):17314-27.
-
Zhang X, Kong Y, Zhang J, Su M, Zhou Y, Zang Y, Li J, Chen Y, Fang Y, Zhang X, Lu W. Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors. Eur J Med Chem. 2015 May 05; 95:127-35.
-
Usmani SZ, Lonial S. Novel drug combinations for the management of relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S71-7.
-
Gao M, Gao L, Tao Y, Hou J, Yang G, Wu X, Xu H, Tompkins VS, Han Y, Wu H, Zhan F, Shi J. Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells. Acta Biochim Biophys Sin (Shanghai). 2014 Jun; 46(6):484-91.
-
Pawlyn C, Kaiser MF, Davies FE, Morgan GJ. Current and potential epigenetic targets in multiple myeloma. Epigenomics. 2014 Apr; 6(2):215-28.
-
Zhang X, Bao B, Yu X, Tong L, Luo Y, Huang Q, Su M, Sheng L, Li J, Zhu H, Yang B, Zhang X, Chen Y, Lu W. The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase. Bioorg Med Chem. 2013 Nov 15; 21(22):6981-95.
-
Wong HK. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma. Discov Med. 2013 Sep; 16(87):71-8.
-
Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, Wheeler MA, Kelly WK, Tew GN, Saltzman WM, Weiss RM. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine. 2013 Nov; 9(8):1124-34.
-
Zhang X, Su M, Chen Y, Li J, Lu W. The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitors. Molecules. 2013 Jun 03; 18(6):6491-503.
-
de Conti A, Tryndyak V, Koturbash I, Heidor R, Kuroiwa-Trzmielina J, Ong TP, Beland FA, Moreno FS, Pogribny IP. The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway. Carcinogenesis. 2013 Aug; 34(8):1900-6.
-
Zhang X, Zhang J, Tong L, Luo Y, Su M, Zang Y, Li J, Lu W, Chen Y. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents. Bioorg Med Chem. 2013 Jun 01; 21(11):3240-4.
-
Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther. 2013 Jun; 12(6):1140-50.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|